0001209191-17-047716.txt : 20170804
0001209191-17-047716.hdr.sgml : 20170804
20170804164206
ACCESSION NUMBER: 0001209191-17-047716
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170802
FILED AS OF DATE: 20170804
DATE AS OF CHANGE: 20170804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chodakewitz Jeffrey
CENTRAL INDEX KEY: 0001610876
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 171009147
MAIL ADDRESS:
STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC.
STREET 2: 480 ARSENAL ST., SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001610876
Chodakewitz Jeffrey
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP GMDA, CMO
Common Stock
2017-08-02
4
M
0
1796
91.05
A
116220
D
Common Stock
2017-08-02
4
S
0
500
152.50
D
115720
D
Common Stock
2017-08-02
4
S
0
600
153.93
D
115120
D
Common Stock
2017-08-02
4
S
0
400
154.89
D
114720
D
Common Stock
2017-08-02
4
S
0
296
156.24
D
114424
D
Common Stock
2017-08-03
4
M
0
3594
109.14
A
118018
D
Common Stock
2017-08-03
4
S
0
600
153.29
D
117418
D
Common Stock
2017-08-03
4
S
0
2494
154.21
D
114924
D
Common Stock
2017-08-03
4
S
0
500
155.15
D
114424
D
Stock Option (Right to Buy)
91.05
2017-08-02
4
M
0
1796
0.00
D
2026-02-01
Common Stock
1796
17960
D
Stock Option (Right to Buy)
109.14
2017-08-03
4
M
0
3594
0.00
D
2025-02-02
Common Stock
3594
21563
D
Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $152.50 (range $152.00 to $152.88).
Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $153.93 (range $153.31 to $154.30).
Open market sales reported on this line occurred at a weighted average price of $154.89 (range $154.70 to $155.40).
Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.94 to $156.40).
Open market sales reported on this line occurred at a weighted average price of $153.29 (range $152.63 to $153.55).
Open market sales reported on this line occurred at a weighted average price of $154.21 (range $153.71 to $154.64).
Open market sales reported on this line occurred at a weighted average price of $155.15 (range $154.73 to $155.53).
The option vests in 16 quarterly installments from 2/2/2016.
The option vests in 16 quarterly installments from 2/3/2015.
/s/ Omar White, Attorney-in-Fact
2017-08-04